Site comparison · Strategic positioning
Amavita Research vs. CROs without an in-house cardiology practice
The structural difference that separates a continuously-recruiting cardiology practice from a CRO sourcing patients from referral networks.
Powered by amavita Heart and Vascular Health®
Amavita Research is the dedicated research arm of amavita Heart and Vascular Health® — the largest independent cardiovascular practice in South Florida and the largest cardiology practice in Miami owned by a private physician (Dr. Pedro Martinez-Clark, MD, P.A.), independent of any academic medical system.
Sponsors get enrollment from a continuously-recruiting cardiology practice with a high cardiovascular patient volume — not a CRO sourcing from referral networks. That is a structural difference, not a marketing line.
How the two operating models actually enroll patients
Educational summary of the typical CRO-without-practice model. We do not make claims about any specific organization's current operations.
Amavita Research — in-house cardiology practice
Continuous patient pipeline
Cardiovascular patients walk in for routine care every business day. There is no enrollment campaign to launch when a new protocol opens — the pipeline is already running.
Real-time eligibility screening
PIs see candidates at the moment of clinical care. Inclusion / exclusion review happens in the exam room, not weeks later through a recruitment vendor's intake funnel.
Same-building conversion
Consent, screening visits, and trial enrollment happen in the same building as the cardiology visit. No external referral handoff, no patient drop-off between systems.
Diagnostic depth on day one
Because patients are existing cardiology patients, the practice already has their imaging, labs, and history. Screen-fail rates fall and randomization timelines compress.
CRO / site without an in-house cardiology practice (typical model)
- Sources patients from third-party referral networks, recruitment vendors, or paid advertising.
- Each channel adds latency between protocol open and first randomization.
- Conversion depends on someone else's calendar — referring physicians, list vendors, ad funnels.
- Enrollment cost-per-randomized-patient is variable and often unpredictable.
- No structural insulation against recruitment-vendor underperformance.
Why this compounds
Each week of recruitment latency is a week of trial latency
On a multi-site Phase 2-3 cardiovascular program, the rate-limiting site sets the timeline for the whole study. A site whose recruitment depends on third-party referrals carries structural latency: the protocol opens, but patients still have to be identified, referred, contacted, and converted by external partners.
A site with an in-house cardiology practice does not have that latency. Trial-eligible patients are already in the room. The conversation moves from "let me explain what a clinical trial is" to "this protocol matches your case — can we screen you next week." That difference compounds across every randomization in the cohort.
Frequently asked questions
Why does an in-house cardiology practice matter for clinical trial enrollment?
Because trial-eligible cardiovascular patients walk into the practice for routine care every day. PIs see them at the point of cardiology care, screen them in real time, and convert them in the same building — no referral letters, no third-party gatekeeping, no recruitment-vendor lag.
How is this different from a CRO without an in-house practice?
Independent CROs and sites without a parent practice must source patients from external referral networks, recruitment vendors, EMR list-buys, or paid advertising. Each of those channels adds time, cost, and uncertainty. Enrollment depends on someone else's calendar.
What is amavita Heart and Vascular Health®?
It is the largest independent cardiovascular practice in South Florida — the largest cardiology practice in Miami owned by a private physician (Dr. Pedro Martinez-Clark, MD, P.A.), independent of any academic medical system. Amavita Research is its dedicated research arm.
Does the parent practice limit Amavita Research's sponsor work to the practice's patients?
No. The parent practice is the baseline patient feeder — a continuous, pre-qualified cardiovascular pipeline. Amavita Research also runs community outreach, bilingual recruitment, and the standard sponsor-funded recruitment channels on top of it.
Can a CRO replicate this with a referral agreement?
A referral agreement is a contract; an in-house practice is an operating reality. Patients are already in the cardiology workflow at amavita Heart and Vascular Health®. Conversion to a trial cohort happens during the visit, not weeks later through a separate intake funnel.
Next step
Schedule a 20-minute capabilities call
See enrollment cadence data from a continuously-recruiting cardiology practice. Same-business-day response from a single owner.